Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06266000
Registration number
NCT06266000
Ethics application status
Date submitted
31/01/2024
Date registered
20/02/2024
Date last updated
4/04/2024
Titles & IDs
Public title
Comparison of 2 Extracts of Saw Palmetto Versus Placebo on BPH Symptoms
Query!
Scientific title
A Study to Compare 2 Extracts of Saw Palmetto Versus Placebo on the Symptoms of Beni
Query!
Secondary ID [1]
0
0
PROPAL
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Benign Prostatic Hyperplasia
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Saw palmetto extract 320mg per day
Treatment: Drugs - Commercial Saw palmetto extract 320mg per day
Treatment: Drugs - Palm Oil capsule
Experimental: Saw palmetto extract - Saw palmetto extract taken as 2 capsules per day
Active Comparator: Comparator saw palmetto extract - Commercial saw palmetto extract taken as 2 capsules per day
Placebo Comparator: Placebo - Palm oil taken as 2 capsules per day
Treatment: Drugs: Saw palmetto extract 320mg per day
Saw palmetto extract 160mg per capsule
Treatment: Drugs: Commercial Saw palmetto extract 320mg per day
Saw palmetto extract 160mg per capsule
Treatment: Drugs: Palm Oil capsule
Palm oil capsule
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
International Prostate Symptom Score (IPSS)
Query!
Assessment method [1]
0
0
Change from baseline to the end of the study period in the International Prostate Symptom Score (IPSS).The total score can range from 0 to 35 i.e. asymptomatic to very symptomatic.
Query!
Timepoint [1]
0
0
Day 0, Day 28, Day 56, Day 84
Query!
Primary outcome [2]
0
0
Daily Urinary Frequency Diary
Query!
Assessment method [2]
0
0
Change from baseline to the end of the study period in Daily Urinary Frequency Diary
Query!
Timepoint [2]
0
0
Day 0, Days 21-27, Day 49-55, Day 77-83
Query!
Secondary outcome [1]
0
0
Brief Sexual Function Inventory (BSFI)
Query!
Assessment method [1]
0
0
Change from baseline to the end of the study period in Brief Sexual Function Inventory (BSFI). The total score can range from 0 to 44 with higher scores indicating better outcomes.
Query!
Timepoint [1]
0
0
Day 0, Day 28, Day 56, Day 84
Query!
Secondary outcome [2]
0
0
International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Module (ICIQ-MLUTS)
Query!
Assessment method [2]
0
0
Change from baseline to the end of the study period in International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms (ICIQ-MLUTS). The total score can range from 1 to 84 with higher scores indicating worse outcomes.
Query!
Timepoint [2]
0
0
Day 0, Day 84
Query!
Secondary outcome [3]
0
0
Electrolytes (E/LFT) blood test
Query!
Assessment method [3]
0
0
Change from baseline to the end of the study period in electrolytes measured via E/LFT blood test.
Query!
Timepoint [3]
0
0
Day 0, Day 84
Query!
Secondary outcome [4]
0
0
Liver Function (E/LFT) blood test
Query!
Assessment method [4]
0
0
Change from baseline to the end of the study period in liver function measured via E/LFT blood test.
Query!
Timepoint [4]
0
0
Day 0, Day 84
Query!
Secondary outcome [5]
0
0
Inflammatory marker - JM27
Query!
Assessment method [5]
0
0
Change from baseline to the end of the study period in Inflammatory marker - JM27 assessed via blood test
Query!
Timepoint [5]
0
0
Day 0, Day 84
Query!
Secondary outcome [6]
0
0
Blood pressure
Query!
Assessment method [6]
0
0
Change from baseline to the end of the study period in blood pressure
Query!
Timepoint [6]
0
0
Day 0, Day 84
Query!
Secondary outcome [7]
0
0
Pulse rate
Query!
Assessment method [7]
0
0
Change from baseline to the end of the study period in pulse rate
Query!
Timepoint [7]
0
0
Day 0, Day 84
Query!
Secondary outcome [8]
0
0
Adverse event frequency
Query!
Assessment method [8]
0
0
Change in safety as assessed by adverse events frequency
Query!
Timepoint [8]
0
0
During enrolment period
Query!
Secondary outcome [9]
0
0
Adverse event severity
Query!
Assessment method [9]
0
0
Change in safety as assessed by adverse events severity
Query!
Timepoint [9]
0
0
During enrolment period
Query!
Secondary outcome [10]
0
0
Discontinuation due to adverse events
Query!
Assessment method [10]
0
0
Number of participants who discontinue study due to adverse events.
Query!
Timepoint [10]
0
0
During enrolment period
Query!
Eligibility
Key inclusion criteria
- Male aged between 45-80
- Medically diagnosed with BPH (Participant to provide written evidence of medical
diagnosis)
- Score of 12-19 in the IPSS (moderate)
- Generally healthy
- Able to provide informed consent
- Agree not to participate in another clinical trial while enrolled in this trial
- Agree not the change their diet or exercise while enrolled in this trial
Query!
Minimum age
45
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Serious illness e.g., mood disorders such as depression, anxiety or bipolar disorder,
neurological disorders such as MS, kidney disease, liver disease or heart conditions
(A serious illness is a condition that carries a risk of mortality, negatively impacts
quality of life and daily function and/or is burdensome in symptoms and/or treatments)
- Unstable illness e.g., diabetes and thyroid gland dysfunction (An unstable illness is
any illness that is currently not being treated with a stable dose of medication or is
fluctuating in severity)
- Have used a drug/natural therapy for BPH or other urological symptoms within the last
30 days?
- Have had a urinary infection in the last 30 days or have, chronic urinary tract
infections, or diagnosed chronic prostatitis
- Have had urogenital surgery within the last 6 months.
- Have had a bladder biopsy and/or cystoscopy and biopsy within the past 30 days.
- Have been diagnosed with chronic persistent local pathology (e.g. interstitial
cystitis, bladder stones)
- Receiving/ prescribed Coumadin (Warfarin) or other anticoagulation therapy
- Diagnosed genital anatomical deformities, uncontrolled diabetes mellitus, and history
of spinal cord injury, uncontrolled psychiatric disorder, and/or abnormal secondary
sexual characteristics.
- Diagnosed cancer including prostatic cancer; if suspected by the investigator, refer
for medical assessment
- Active smokers and/or nicotine or drug abuse
- Chronic alcohol use (>14 alcoholic drinks week)
- Allergic to any of the ingredients in investigational, comparator or placebo formula
- Any condition which in the opinion of the investigator makes the participant
unsuitable for inclusion
- Participated in any other clinical trial during the past 1 month
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/03/2025
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
RDC Clinical Pty Ltd - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4006 - Brisbane
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
RDC Clinical Pty Ltd
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A randomized, double-blind, placebo-controlled, parallel group study to compare 2 extracts of
saw palmetto versus placebo on the symptoms of benign prostate hyperplasia (BPH) in 120
generally healthy participants, 45 - 80 years.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06266000
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Amanda Rao, PhD
Query!
Address
0
0
RDC Clinical Pty Ltd
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Amanda Rao, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 414 488 559
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06266000
Download to PDF